Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benlysta Decision Likely To Be Delayed By Negotiations On Labeling

Executive Summary

The Arthritis Advisory Committee's call for FDA to tailor labeling to restrict claims of efficacy to the clinical trial population for Human Genome Sciences' lupus drug Benlysta (belimumab) will likely push a decision on the drug beyond its Dec. 9 user fee date.

You may also be interested in...



Benlysta In GSK’s Hands: A Slow-but-steady Launch, Or A Dud?

With GlaxoSmithKline and Human Genome Sciences agreeing to a merger July 16, the key question for the multinational pharma becomes what it will do to strengthen sales for Benlysta, a lupus drug launched in 2011 that has fallen short of bullish commercial expectations.

HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions

The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.

HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions

The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.

Related Content

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel